February 1, 2021

Aizon Launches GxP AI Bioreactor Application for the Pharma Industry to Scale Manufacturing & Quality

Share this post

The application makes the power of AI accessible to pharma manufacturing while preserving GxP compliance, enabling data-driven decisions faster in the pursuit of bioreactor process optimization.

SAN FRANCISCO – (February 1, 2021) – Aizon launches its Bioreactor Application, the pharma industry’s first predictive analysis and deep knowledge management application. The Aizon Bioreactor Application adds the bioreactor process to the “Smart Manufacturing” transformation that is accelerating across the Pharma and Biotech industry. Aizon is uniquely able to achieve GxP compliance and provide an audit trail from the start of the process. The turnkey application allows pharmaceutical and biotech companies to leverage rich datasets generated during upstream manufacturing to detect and accurately predict deviations and outcomes—potentially leading to hundreds of millions of dollars in cost savings, reduced risk, and additional revenue upside.

Designed to work with both continuous and fed-batch bioreactors, the Aizon Bioreactor Application provides a deep understanding of the customer’s bioprocess manufacturing lifecycle. The application leverages specialized Edge AI and contextualization, which is a requirement to make the data actionable. Contextualized data is harnessed, analyzed, and visualized through a persona-based lens for faster root cause analysis (RCA), real-time monitoring, and predictive insight across any number of bioreactor units and manufacturing sites.

AI models for bioreactor analytics are ready for use within the application or can be configured by customers within the GxP cloud-based application. “It is clear that biotech and pharmaceutical companies need an accessible, industry-specific tool that accelerates their path to value. Customers seek a seamless way to analyze complex data sets in real-time and to predict with accuracy the yield from bioreactor units that span multiple sites and global regions,” said Pep Gubau, CTO, Aizon. “Biotech and pharmaceutical companies can now more easily leverage the power of AI/ML in a GxP environment with an end-to-end lifecycle governance of data, models, and applications in order to understand and optimize bioreactor processes in commercial manufacturing.”
Aizon’s CEO, John Vitalie adds, ”Our focus is to empower customers to innovate and rapidly achieve their targeted outcomes without the overhead burden of tracking changes, revalidation, and on-going development to maintain compliance. By building the process knowledge framework, compliance, and scalability into the application, customers benefit significantly from the streamlined industrialization of their digital solutions. We see that this is key for pharma and biotech to realize the vision of smart manufacturing and accelerate their progress toward realizing the promise of the adaptive plant.”

Pharmaceutical and biotech companies can use the Aizon Bioreactor Application to further their digital transformation journey towards Pharma 4.0 and future-proof the path to continued process verification (CPV).

The Aizon Bioreactor Application is generally available to pharmaceutical and biotechnology manufacturers today as a single application or as a seamless solution within Aizon’s Enterprise Platform. Contact sales@aizon.ai or download the data sheet for information.


About Aizon

Aizon is an enterprise software provider that transforms manufacturing operations with the use of advanced analytics, artificial intelligence, and other smart factory technologies focused on optimizing production within Pharma and other highly regulated industries. The Aizon AI platform and native GxP based applications seamlessly integrate unlimited sources of structured and unstructured data to deliver actionable, real-time insights across all manufacturing sites. Aizon brings deep domain expertise and works closely with Global System Integrators and technology partners to provide enterprise solutions to customers.